Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of formula I:



I

wherein A is



,

R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, and R^5 is $-M-L^1$; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-12}-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; $-COOR^1$; $-NHCOR^1$; $-CN$; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;

M is $-CH_2-$, -S-, $-N(CH_3)-$, -NHC(O)- $-CH_2-S-$, $-S-CH_2-$, -C(O)-, or –O-; and

L^1 is phenyl, substituted by C_{1-10}-alkoxy, OH, $-SCH_3$, or by



pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, -OH, $-SCH_3$ or NO_2 ,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, OH, $-SCH_3$ or NO_2, and wherein the compound of formula I has a pKa greater than 10,

or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Previously Presented) A compound according to claim 1, wherein

R^3 is H, halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H, C_{1-10}- alkoxy, thiophene, pyrole or methyl substituted pyrole,

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3, CF_3 or $-OCH_3$.

4. (Previously Presented) A compound according to claim 1, wherein

$R^{3'}$ is C_{4-10}-alkyl, Cl, F or CF_3;

$R^{4'}$ is H, Cl or F ;

$R^{5'}$ is H, Cl, F or C_{4-10}-alkyl; and

$R^{6'}$ is H or OCH_3.

5. (Previously Presented) A compound according to claim 4, wherein $R^{3'}$ or $R^{5'}$ is t-butyl.

6. (Previously Presented) A compound according to claim 1, wherein M is $-CH_2-$, -$N(CH_3)$- or –NHC(O)-.

7. (Previously Presented) A compound according to claim 6, wherein L^1 is phenyl or pyridyl.

8. (Previously Presented) A compound according to claim 1, wherein M is –O-.

9. (Previously Presented) A compound according to claim 8, wherein L^1 is phenyl, pyridyl, pyridone or benzothiazole.

10. (Previously Presented) A compound according to claim 1, wherein M is –S-.

11. (Previously Presented) A compound according to claim 10, wherein L^1 is phenyl or pyridyl.

12. (Previously Presented) A compound of the formula



13. (Original) A pharmaceutical composition comprising a compound of claim 1, and a physiologically acceptable carrier.

14. (Original) A pharmaceutical composition comprising a compound of claim 12, and a physiologically acceptable carrier.

15. (Cancelled)

16. (Previously Presented) A method for the treatment of a cancerous cell growth mediated by raf kinase, comprising administering a compound of formula IIa:



IIa

wherein A is



,

R^3, R^4, R^5 and R^6 are each independently H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, R^5 and R^6 is $-M-L^1$; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl; C_{6-12}-aryl, C_{5-12}-hetaryl, C_{6-12}-alkaryl, halogen; $-NR^1R^1$; $-NO_2$; $-CF_3$;$-COOR^1$; $-NHCOR^1$; -CN; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen, up to perhalo and

R^2 is C_{1-10}-alkyl, optionally substituted by halogen,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen, C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl, C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl, halogen up to perhalo;

M is $-CH_2-$, -S-, $-N(CH_3)-$, -NHC(O)- $-CH_2-S-$, $-S-CH_2-$, -C(O)-, or –O-; and

L^1 is phenyl, pyridyl, naphthyl, pyridone, pyrazine, pyrimidine, benzodiaxane, benzopyridine or benzothiazole, each optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, NO_2 or, where Y is phenyl, by



or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A method according to claim 16, wherein

R^3 is halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H , C_{1-10}- alkoxy, thiophene, pyrole or methylsubstituted pyrole

$R^{3'}$ is H, halogen, C_{4-10}-alkyl, or CF_3 and

$R^{6'}$ is H, halogen, CH_3 , CF_3 or OCH_3.

18. (Previously Presented) A method according to claim 16, wherein M is -CH_2- ,–S-, -$N(CH_3)$- or –NHC(O)- and L^1 is phenyl or pyridyl.

19. (Previously Presented) A method according to claim 16, wherein M is –O- and L^1 is phenyl, pyridone, pyrimidine, pyridyl or benzothiazole.

20. (Cancelled)

21. (Previously Presented) A compound of formula I:



BAYER-0006-P01

I

wherein A is



wherein

R^3 is H, halogen or C_{1-10}- alkyl, optionally substituted by halogen, up to perhaloalkyl;

R^4 is H, halogen or NO_2;

R^5 is H, halogen or C_{1-10}- alkyl;

R^6 is H, C_{1-10}- alkoxy, thiophene, pyrole or methyl substituted pyrole,

$R^{3'}$ is H, Cl, F, C_{4-10}-alkyl, or CF_3 and

$R^{4'}$ is H, Cl or F ;

$R^{5'}$ is H, Cl, F or C_{4-10}-alkyl; and

$R^{6'}$ is H, halogen, CH_3, CF_3 or $-OCH_3$,.

and one of R^3, R^4, and R^5 is –M-L^1; wherein

M is $–CH_2-$, -S-, $-N(CH_3)-$, -NHC(O)- $-CH_2-S-$, $-S-CH_2-$, -C(O)-, or –O-; and

L^1 is phenyl, substituted by C_{1-10}-alkoxy, OH, $-SCH_3$, or by



pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, $-SCH_3$ or NO_2, and wherein the compound of formula I has a pKa greater than 10,

or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) A compound according to claim 21, wherein $R^{3'}$ or $R^{5'}$ is t-butyl.

23. (Previously Presented) A compound according to claim 21, wherein M is $-CH_2-$, $-N(CH_3)-$ or $-NHC(O)-$.

24. (Previously Presented) A compound according to claim 21, wherein L^1 is phenyl or pyridyl.

25. (Previously Presented) A compound according to claim 21, wherein M is –S-.

26. (Previously Presented) A compound according to claim 25, wherein L^1 is phenyl or pyridyl.

27. (Previously Presented) A compound of formula I:



I

wherein A is



,

R^3, R^4, R^5 and R^6 are each, independently, H, halogen, NO_2,

C_{1-10}- alkyl, optionally substituted by halogen up to perhaloalkyl,

C_{1-10}-alkoxy, optionally substituted by halogen up to perhaloalkoxy,

C_{1-10}- alkanoyl, optionally substituted by halogen up to perhaloalkanoyl,

C_{6-12} aryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy, or

C_{5-12} hetaryl, optionally substituted by C_{1-10} alkyl or C_{1-10} alkoxy,

and either

one of R^3, R^4, and R^5 is –M-L^1; or

two adjacent of R^3, R^4, R^5 and R^6 together are an aryl or hetaryl ring with 5-12 atoms, optionally substituted by C_{1-10}-alkyl, , halo-substituted C_{1-10}-alkyl up to perhaloalkyl, C_{1-10}-alkoxy, halo-substituted C_{1-10}-alkoxy up to perhaloalkoxy, C_{3-10}-cycloalkyl, C_{2-10}-alkenyl, C_{1-10}-alkanoyl, C_{6-}

$_{12}$-aryl, C_{5-12}-hetaryl; C_{6-12}-aralkyl, C_{6-12}-alkaryl, halogen; NR^1R^1; $-NO_2$; $-CF_3$; $-COOR^1$; $-NHCOR^1$; -CN; $-CONR^1R^1$; $-SO_2R^2$; $-SOR^2$; $-SR^2$;

in which

R^1 is H or C_{1-10}-alkyl, optionally substituted by halogen up to perhaloalkyl and R^2isC_{1-10}-alkyl, optionally substituted by halogen, up to perhaloalkyl,

$R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$ are independently H, halogen,

C_1 - C_{10} alkyl, optionally substituted by halogen up to perhaloalkyl,

C_1 –C_{10} alkoxy optionally substituted by halogen up to perhaloalkoxy or two adjacent of $R^{3'}$, $R^{4'}$, $R^{5'}$ and $R^{6'}$, together with the base phenyl, form a naphthyl group, optionally substituted by halogen up to perhalo, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkanoyl, C_{6-12} aryl, C_{5-12} hetaryl or C_{6-12} aralkyl;

M is –CH_2-, -S-, -N(CH_3)-, -NHC(O)- -CH_2-S-, -S-CH_2-, -C(O)-, or –O-; and

L^1 is phenyl, substituted by C_{1-10}-alkoxy, OH, $-SCH_3$, or by



pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, OH, $-SCH_3$ or NO_2,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, OH, $-SCH_3$ or NO_2, or a pharmaceutically acceptable salt thereof.

28. (Previously Presented) A method according to claim 16, wherein lung carcinoma is treated.

29. (Previously Presented) A method according to claim 16, wherein pancreas carcinoma is treated.

30. (Previously Presented) A method according to claim 16, wherein thyroid carcinoma is treated.

31. (Previously Presented) A method according to claim 16, wherein bladder carcinoma is treated.

32. (Previously Presented) A method according to claim 16, wherein colon carcinoma is

treated.

33. (Previously Presented) A method according to claim 16, wherein myeloid leukemia is treated.

34. (Previously Presented) A compound according to claim 27, wherein

L^1 is phenyl, substituted by C_{1-10}-alkoxy, $-SCH_3$, or by



pyridyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$, or NO_2,

naphthyl, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyridone, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyrazine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

pyrimidine, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

benzodioxane, optionally substituted by C_{1-10}-alkyl, C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

benzopyridine, optionally substituted by C_{1-10}-alkyl, one C_{1-10}-alkoxy, halogen, $-SCH_3$ or NO_2,

or

benzothiazole, optionally substituted by, C_{1-10} alkyl C_{1-10} alkoxy, halogen, $-SCH_3$ or NO_2.